Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
AMG 305 in Advanced Solid Tumors
NCT05800964Phase 1Terminated
- Sponsor
- Amgen
- Start
- Jun 2023
- Primary completion
- Jan 2026
- Modality
- Bispecific Antibodies, Monoclonal Antibodies
- Countries
- 9
01
Overview
Phase 1, open-label trial of AMG 305 in solid tumor (advanced stage) (2 arms), sponsored by Amgen. Primary endpoints: Dose Limiting Toxicities, Treatment-Emergent Adverse Events up to 2 years and 1 more. Started Jun 2023; status: terminated.
02
Drugs
AMG 305
03
Conditions
solid tumor (advanced stage)
Beyond the preview
Go deeper on NCT05800964.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05800964.